Insulet [PODD] vs Abbott Laboratories [ABT] Detailed Stock Comparison
Insulet
NASDAQ
Loading...
Abbott Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Insulet wins in 5 metrics, Abbott Laboratories wins in 14 metrics, with 0 ties. Abbott Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Insulet | Abbott Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 94.24 | 16.89 | Abbott Laboratories |
| Price-to-Book Ratio | 14.87 | 4.63 | Abbott Laboratories |
| Debt-to-Equity Ratio | 99.49 | 26.50 | Abbott Laboratories |
| PEG Ratio | -1.07 | 0.46 | Insulet |
| EV/EBITDA | 45.96 | 21.02 | Abbott Laboratories |
| Profit Margin (TTM) | 10.01% | 32.43% | Abbott Laboratories |
| Operating Margin (TTM) | 18.66% | 19.73% | Abbott Laboratories |
| EBITDA Margin (TTM) | 18.66% | 19.73% | Abbott Laboratories |
| Return on Equity | 19.18% | 30.93% | Abbott Laboratories |
| Return on Assets (TTM) | 7.75% | 6.62% | Insulet |
| Free Cash Flow (TTM) | $296.30M | $6.35B | Abbott Laboratories |
| Dividend Yield | N/A | 1.28% | N/A |
| 1-Year Return | 34.47% | 14.55% | Insulet |
| Price-to-Sales Ratio (TTM) | 9.22 | 5.43 | Abbott Laboratories |
| Enterprise Value | $22.09B | $240.70B | Abbott Laboratories |
| EV/Revenue Ratio | 9.36 | 5.58 | Abbott Laboratories |
| Gross Profit Margin (TTM) | 69.67% | 56.44% | Insulet |
| Revenue per Share (TTM) | $34 | $25 | Insulet |
| Earnings per Share (Diluted) | $3.28 | $7.97 | Abbott Laboratories |
| Beta (Stock Volatility) | 1.40 | 0.70 | Abbott Laboratories |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Insulet vs Abbott Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Insulet | 0.56% | 1.53% | -10.33% | 4.24% | 22.33% | 22.04% |
| Abbott Laboratories | -0.54% | -0.69% | 0.62% | -0.51% | 6.54% | 17.26% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Insulet | 34.47% | 41.76% | 26.22% | 914.07% | 1,872.62% | 1,964.89% |
| Abbott Laboratories | 14.55% | 31.81% | 21.28% | 215.04% | 421.40% | 550.10% |
News Based Sentiment: Insulet vs Abbott Laboratories
Insulet
News based Sentiment: MIXED
Insulet reported exceptional Q2 results and raised guidance, indicating strong growth. However, a Goldman Sachs price target cut and insider selling created market headwinds, resulting in a mixed investment narrative. The combination of positive financial performance and negative market reactions makes this a significant month for the company.
Abbott Laboratories
News based Sentiment: POSITIVE
Abbott Laboratories delivered strong Q2 earnings and raised guidance, leading to positive analyst revisions and continued institutional investment. While some valuation models suggest the stock may be overvalued, the overall narrative is positive, driven by strong financial performance and a promising product pipeline.
Performance & Financial Health Analysis: Insulet vs Abbott Laboratories
| Metric | PODD | ABT |
|---|---|---|
| Market Information | ||
| Market Cap | $22.61B | $234.39B |
| Market Cap Category | Large cap | Mega cap |
| 10 Day Avg. Volume | 676,650 | 5,683,430 |
| 90 Day Avg. Volume | 637,977 | 5,498,563 |
| Last Close | $313.45 | $133.02 |
| 52 Week Range | $225.37 - $353.50 | $110.86 - $141.23 |
| % from 52W High | -11.33% | -5.81% |
| All-Time High | $353.50 (Sep 09, 2025) | $142.60 (Dec 27, 2021) |
| % from All-Time High | -11.33% | -6.72% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.33% | 0.07% |
| Quarterly Earnings Growth | -0.88% | 0.37% |
| Financial Health | ||
| Profit Margin (TTM) | 0.10% | 0.32% |
| Operating Margin (TTM) | 0.19% | 0.20% |
| Return on Equity (TTM) | 0.19% | 0.31% |
| Debt to Equity (MRQ) | 99.49 | 26.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $20.78 | $29.05 |
| Cash per Share (MRQ) | $15.93 | $4.18 |
| Operating Cash Flow (TTM) | $516.20M | $9.04B |
| Levered Free Cash Flow (TTM) | $112.66M | $5.92B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.28% |
| Last 12-Month Dividend | N/A | $1.69 |
Valuation & Enterprise Metrics Analysis: Insulet vs Abbott Laboratories
| Metric | PODD | ABT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 94.24 | 16.89 |
| Forward P/E | 79.87 | 26.08 |
| PEG Ratio | -1.07 | 0.46 |
| Price to Sales (TTM) | 9.22 | 5.43 |
| Price to Book (MRQ) | 14.87 | 4.63 |
| Market Capitalization | ||
| Market Capitalization | $22.61B | $234.39B |
| Enterprise Value | $22.09B | $240.70B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 9.36 | 5.58 |
| Enterprise to EBITDA | 45.96 | 21.02 |
| Risk & Other Metrics | ||
| Beta | 1.40 | 0.70 |
| Book Value per Share (MRQ) | $20.78 | $29.05 |
Financial Statements Comparison: Insulet vs Abbott Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PODD | ABT |
|---|---|---|
| Revenue/Sales | $569.00M | $10.36B |
| Cost of Goods Sold | $160.00M | $4.47B |
| Gross Profit | $409.00M | $5.89B |
| Research & Development | $59.60M | $716.00M |
| Operating Income (EBIT) | $88.80M | $1.69B |
| EBITDA | $118.50M | $2.66B |
| Pre-Tax Income | $48.10M | $1.78B |
| Income Tax | $12.70M | $453.00M |
| Net Income (Profit) | $35.40M | $1.33B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PODD | ABT |
|---|---|---|
| Cash & Equivalents | $1.28B | $6.53B |
| Total Current Assets | $2.33B | $23.15B |
| Total Current Liabilities | $520.40M | $13.00B |
| Long-Term Debt | $1.61B | $12.74B |
| Total Shareholders Equity | $1.33B | $49.06B |
| Retained Earnings | $75.70M | $47.72B |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PODD | ABT |
|---|---|---|
| Operating Cash Flow | $81.00M | $1.42B |
| Capital Expenditures | N/A | $-484.00M |
| Free Cash Flow | $48.10M | $933.00M |
| Debt Repayment | $-182.70M | $-1.00B |
| Common Stock Repurchase | N/A | $-280.00M |
Short Interest & Institutional Ownership Analysis
| Metric | PODD | ABT |
|---|---|---|
| Shares Short | 1.50M | 18.07M |
| Short Ratio | 2.75 | 3.68 |
| Short % of Float | 0.03% | 0.01% |
| Average Daily Volume (10 Day) | 676,650 | 5,683,430 |
| Average Daily Volume (90 Day) | 637,977 | 5,498,563 |
| Shares Outstanding | 70.20M | 1.73B |
| Float Shares | 70.08M | 1.73B |
| % Held by Insiders | 0.00% | 0.01% |
| % Held by Institutions | 1.02% | 0.81% |
Dividend Analysis & Yield Comparison: Insulet vs Abbott Laboratories
| Metric | PODD | ABT |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.69 |
| Last 12-Month Dividend Yield | N/A | 1.28% |
| 3-Year Avg Annual Dividend | N/A | $1.92 |
| 3-Year Avg Dividend Yield | N/A | 0.49% |
| 3-Year Total Dividends | N/A | $5.77 |
| Ex-Dividend Date | N/A | Jan 15, 2025 |